施福东

MD / PhD
京津神经免疫中心

个人概括

1966年生,瑞典Karolinska学院神经病学博士,主任医师,擅长神经免疫和炎性疾病,包括多发性硬化,视神经脊髓炎,重症肌无力等疾病的诊断和治疗。

施福东分别在哈尔滨医科大学,北京协和医院,瑞典Karolinska学院,美国Scripps研究院,美国St. Joseph医院Barrow神经病学研究所先后完成临床和科研训练。 “长江学者”特聘教授、国家“千人计划”,国家重大科学研究计划项目(973)首席科学家。学术兼职包括泛亚多发性硬化治疗和研究委员会(PACTRIMS)委员,中华医学会神经病学分会委员会常务委员,天津市医学会神经病学分会主任委员。获得首届“中国卒中创新研究奖”、第三届“中国卒中奖”、“中国杰出神经内科医师”称号。获得美国发明专利1项。

施福东长期致力于研究天然免疫在神经疾病中的作用,并探索新的免疫治疗策略。近年发现了脑内炎症和免疫反应的特异性,完善了神经免疫疾病的实验室辅助诊断,寻找出适合我国国情的视神经脊髓炎的治疗方案,对脑血管病的免疫机制和免疫干预进行了开创性的探索。在Nat Immunol, PNAS, Nat Rev Immunol, J Exp Med, Ann Neurol, Neurology, JAMA Neurology, Circulation, Nat Rev Neurol, Nat Neurosci, Immunity等杂志上发表文章165篇,参编专著11部。

教育和工作经历

  • 1984-1989  哈尔滨医科大学和北京协和医院   临床医学学士学位
  • 1989-1995  哈尔滨医科大学第二医院内科/神经内科  住院医师、硕士研究生、主治医师
  • 1995-1998  瑞典Karolinska 学院神经病学系(www.ki.se)   神经病学博士学位
  • 1999-2003  美国圣地亚歌Scripps 研究所(www.scripps.edu)    博士后
  • 2003-2008  美国Arizona 州St. Joseph’s 医院Barrow神经病学研究所(www.thebarrow.com)    助理教授 (Assistant Professor)
  • 2009-  美国Barrow神经病学研究所  神经病学副教授 (with tenure, 永久)
  • 2010-   Barrow神经病学研究所和亚利桑那大学生命科学院联合神经科学部  教授
  • 2010-   天津医科大学总医院神经内科, 天津市神经病学研究所  “长江学者”特聘教授, 国家“千人计划”、国家特聘专家, 神经内科主任,天津市神经病学研究所副所长
  • 2014-  天津医科大学总医院  副院长
  • 2017-  北京天坛医院,国家神经系统疾病临床医学研究中心,神经免疫中心    神经免疫中心主任,首席科学专家

所获奖项

  • 2014中国侨界(创新人才)贡献奖。
  • 2014 天津市科学技术奖“中枢神经系统炎性脱髓鞘疾病的免疫学、诊断和治疗研究”,科技进步公益类二等奖,第一完成人。
  • 2015年首届“中国卒中创新研究奖”。
  • 2017年度“中国杰出神经内科医师”。
  • 2017年度“中国卒中奖”。

代表性论文

Original articles
  1. Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L, Shi FD. Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. JAMA Neurol. 2017;74(8):1010-1012. 影响因子:10.029.
  2. Jiang W, Li D, Han R, Zhang C, Jin WN, Wood K, Liu Q, Shi FD, Hao J. Acetylcholine-producing NK cells attenuate CNS inflammation via modulation of infiltrating monocytes/macrophages. Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6202-E6211. 影响因子:9.423.
  3. Liu Q, Jin WN, Liu Y, Shi K, Sun H, Zhang F, Zhang C, Gonzales R, Sheth KN, La Cava A, Shi FD. Brain ischemia suppresses immunity in the periphery and brain via different neurogenic innervations. Immunity. 2017 46:474-487. 影响因子:24.082. 引用次数:6.  Immunity社论专题评述: Linda Quatrini1 and Sophie Ugolini1, Disarming the Killers: Brain Strikes on NK Cells. DOI: http://dx.doi.org/10.1016/j.immuni.2017.03.001.
  4. Li M, Li Z, Yao Y, Jin WN, Wood K, Liu Q, Shi FD, Hao J. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc Natl Acad Sci U S A. 2017;114: E396-E405. 影响因子:9.423. 引用次数:5.  Proc Natl Acad Sci U S A社论专题评述: Meaghan Roy-O’Reilly and Louise D. McCullough, Astrocytes fuel the fire of lymphocyte toxicity after stroke. 2017:114,425-427.  
  5. Liu Q, Sanai N, Jin WN, La Cava A, Van Kaer L, and Shi FD. 2016. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci. 19:243-52. 影响因子:16.724. 引用次数:25.  Nature Neuroscience社论专题评述:Jonathan Kipnis, et al. Natural killers in the brain's nursery. 2016:19,176–177.
  6. Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, Dong Y, Xu X, Liu Q, Huang D, Shi FD. 2015. Combination of an immune modulator fingolimod with alteplase in acute ischemic stroke. Circulation. 132:1104-12. 影响因子:17.047. 引用次数:48.
  7. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, Han W, Xue R, Liu Q, Hao J, Yu C, Shi FD. 2014. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 111:18315-20. 影响因子:9.423. 引用次数:61.
  8. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, Yan Y, Huang D, Yu C, Shi FD. 2014. Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study. JAMA Neurol. 71:1092-101. 影响因子:8.23. 引用次数:82.  美国心脏病学学会(AHA)头版头条报道:“Stroke Rounds: An MS Drug for ICH?”;  JAMA Neurology社论专题评述:Kevin N. Sheth and Jonathan Rosand, Targeting the Immune System in Intracerebral Hemorrhage. 2014;71:1083-4.
  9. Gan Y, Liu Q, Wu W, Yin J, Tang Z, Turner G, Chen J, Wang Y, Lanrent J, Yokayama W, Shi FD. 2014. Ischemic neurons recruit NK cells that accelerate brain infarction. Proc Natl Acad Sci USA. 111:2704-9. 影响因子:9.423. 引用次数:63.
  10. Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhang NN, Shao ZH, Yu CS, and Shi FD. 2013. Responsiveness to reduced dosage of rituximab in Chinese neuromyelitis optica patients. Neurology. 81:710-3. 影响因子:8.166. 引用次数:46.
  11. Hao JW, Campagnolo DI, Liu R, Piao WH, Shi S, Hu B, Xiang R, Zhou Q, Vollmer TL, Van Kaer L, La Cava A, and Shi FD. 2011. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol. 69:721-34. 影响因子:9.638. 引用次数:52.
  12. Hao JW, Liu R, Piao WH, Zhou Q, Vollmer TL, Xiang R, La Cava A, Campagnolo DI, Van Kaer L, and Shi FD. 2010. CNS-resident NK cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med. 207:1907-1921. 影响因子:11.24. 引用次数:146.  封面文章和Nature专题报道“Killer cells help”.
  13. Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL, Wilson SB, and Sarvetnick N. 2001. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA. 58:6777-6782. 影响因子:9.423. 引用次数:195.
  14. Shi FD, Wang H, Li H, Hong S, Tanihuchi M, Link H, Van Kaer L, and Ljunggren HG. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol. 1:245-251. 影响因子:19.381. 引用次数:200.

代表性论文

Reviews
  1. Fu Y, Liu Q, Anrather J, Shi FD. 2015. Immune interventions in stroke. Nat Rev Neurol. 11(9):524-35. 影响因子:18.418. 引用次数:49.
  2. Shi FD, Ljunggren HG, La Cava A, Van Kaer, L. 2011. Organ-specific features of NK cells. Nat Rev Immunol. 11, 658-671. 影响因子:39.416. 引用次数: 213. 杂志10周年特别刊出.
  3. Shi FD and Jia JP. 2011. Neurology and neurological practice in China. Neurology. 77:1986-92. 影响因子:8.166. 引用次数:18.
  4. Shi FD and Van Kaer L. 2006. Reciprocal regulation between NK cells and autoreactive T cells. Nat Rev Immunol. 6:751-760. 影响因子:39.416. 引用次数:118.
  5. La Cava A, Van Kaer L, and Shi FD. 2006. CD4+CD25+ regulatory T cells and NKT cells: regulators regulating regulators. Trends Immunol. 27: 322-327. 影响因子:11.433. 引用次数:207.
  6. Shi FD, Ljunggren .G, and Sarvetnick N. 2001. Innate immunity and autoimmunity: from-self protection to self-aggression. Trends Immunol.  22:97-101. 影响因子:11.433. 引用次数:147.   Trends Immunol社论专题评述:  De la Salle H. Autoimmunity mediated by innate immune effector cells. 2001: 22:300-1.

发明专利

序号专利名称申请号码申请日期授权国家
1Nicotine Attenuates the Central Nervous System Inflammation and AutoimmunityUS 8,841,329 B22014.09.23美国, 第一发明人
2芬戈莫德及其结构类似物用于制备治疗脑出血药物的应用201410136059.32014.04.08中国, 第一发明人
3芬戈莫德及其结构类似物用于制备治疗脑梗死药物的应用201410135374.42014.04.08中国, 第一发明人

中国人才基金项目

  • 2009年 “长江学者”特聘教授
  • 2010年 天津市“千人计划”
  • 2011年 国家“千人计划”
  • 2015年 国务院政府特贴专家
  • 2015年第七届国家卫生计生突出贡献中青年专家

海外人才基金项目

  • 2000年 获得青少年糖尿病国际基金 (JDRF) 提供的博士后奖学金 ($160,000 二年)
  • 2002年 获得肌肉萎缩症联合会(MDA)颁发的职业发展奖学金 ($125,000 三年)

在研项目

项目名称:缺血性脑损伤对免疫系统的影响:器官特异性因素,作用机制和临床意义

项目来源:国家自然科学基金重大项目

起止年月:2017–2021

项目经费:200万元

项目分工:项目负责人

已完成项目

1

  • 项目名称:干细胞分化产生的免疫原性与免疫耐受诱导
  • 项目来源:国家重大科学计划项目
  • 起止年月:2013–2017
  • 项目经费:2900万元
  • 项目分工:首席科学家

2

  • 项目名称:自然杀伤细胞和神经干细胞在神经免疫疾病中的相互作用机制
  • 项目来源:国家自然科学基金重点项目
  • 起止年月:2013–2017
  • 项目经费:300万元
  • 项目分工:项目负责人

科研评审:

Grants:

  • 2007  The Juvenile Diabetes Research Foundation (JDRF)-Immunology
  • 2013 – 2014  Italian MS Society; UK Medical Research Council (MRC)
  • 2008 – 2015  National Institute of Health (NIAID): Ad Hoc members for special panels of Autoimmune Centers of Excellence U19; Ancillary Studies in Immunomodulation Clinical Trials; Hypersensitivity, Allergy and Immune Mediated Disease ZRR1; Cooperative Study Group for Autoimmune Disease Prevention; Transplantation, Tolerance, & Tumor Immunology; Allergy, Immunology, and Transplantation Research.
  • 2014 – 2015  Special Emphasis Panels: ZRG1 IMM-K02 and Autoimmunity center of excellence (ACE) AI-14-012/013; NIDDK, ZRG1 IMM-R.

Journals:

  • Nature Medicine, Nature Immunology, PNAS, Immunity, Journal of Clinical Investigation, The Journal Immunology, Neurology, JAMA Neurology, Brain, Neuron.

 

参加科学学会:

  • 2001美国免疫学协会成员
  • 2005美国神经病学协会成员
  • 2013中华医学会神经病学分会第五届委员会常务委员
  • 2014天津神经病学分会主任委员
  • 2015中国卒中学会转化医学分会副主任委员
  • 2015中国卒中学会遗传学分会常务委员
  • 2015中国医师协会神经内科医师分会神经免疫疾病专业委员会副主任委员
  • 2015泛亚多发性硬化治疗和研究委员会(PACTRIMS)委员
  • 2015美国心脏病学学会成员

 

美国和中国执业医师考试及训练:

  • 美国临床执业医师执照的USMLE STEP1(基础医学知识)获得证书时间:1-24-2007
  • 美国临床执业医师执照的USMLE STEP2CK(临床医学知识)获得证书时间:5-12-2008
  • 美国临床执业医师执照的USMLE STEP2CS(临床实践技能)获得证书时间:6-20-2007
  • 通过考试、临床实践及综合评估后获得ECFMG证书; 获得证时间编号:6-9-2008, 0-710-829-3
  • 神经科国际统一EDSS FS 考试; 获得证书时间:12-16-2004
  • 入选美国Barrow临床执业医师神经科训练项目(Match合同编号911.50Barrow N.I. Phoenix)
  • 中国执业医师资格编码 199812110230103
  • 中国执业医师执业编码 110120000030094

 

 

原创性论文(依据疾病种类划分):

视神经脊髓炎疾病谱系疾病/多发硬化:

代表性论文发表在J Exp Med 1, Ann Neurol 1, Neurology 3, Nat Neurosci 1 JAMA Neurol 2

  1. Li T, Zhang LJ, Zhang QX, Yang CS, Zhang C, Li YJ, Shi FD, 2017. Yang L Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab. J Neuroimmunol. pii: S0165-5728(17)30407-1. doi: 10.1016/j.jneuroim.2017.12.021.
  2. Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L, Shi FD. 2017. Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. JAMA Neurol.;74(8):1010-1012. 影响因子:10.029.
  3. Zhang C, Shi FD. 2017. Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms?-Reply. JAMA Neurol. doi: 10.1001/jamaneurol.2017.3450.
  4. Li LM, Zhang C, Zhang LJ, Guo HY, Yang CS, Zhang R, Li YJ, Shi FD, Yang L. 2017. Relapse of neuromyelitis optica associated with oral progestin. J Neurol Neurosurg Psychiatry.
  5. Liu Q, Whiteaker P, Morley BJ, Shi FD, Lukas RJ. 2017. Distinctive Roles for α7*- and α9*-Nicotinic Acetylcholine Receptors in Inflammatory and Autoimmune Responses in the Murine Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. Front Cell Neurosci. 22;11:287.
  6. Tian DC, Su L, Fan M, Yang J, Zhang R, Wen P, Han Y, Yu C, Zhang C, Ren H, Shi K, Zhu Z, Dong Y, Liu Y, Shi FD.2017. Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD). Mult Scler:1352458517727604.
  7. Wang Z, Guo W, Liu Y, Gong Y, Ding X, Shi K, Thome R, Zhang GX, Shi FD, Yan Y. 2017. Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes. Brain Behav Immun. pii: S0889-1591(17)30141-1.
  8. Jiang W, Li D, Han R, Zhang C, Jin WN, Wood K, Liu Q, Shi FD, Hao J. 2017. Acetylcholine-producing NK cells attenuate CNS inflammation via modulation of infiltrating monocytes/macrophages. Proc Natl Acad Sci U S A.114(30):E6202-E6211. 影响因子:9.423.
  9. Liu Y, Duan Y, Huang J, Ren Z, Liu Z, Dong H, Weiler F, Hahn HK, Shi FD, Butzkueven H, Barkhof F, Li K.2017. Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. Eur Radiol. doi: 10.1007/s00330-017-4921-x.
  10. Liu Y, Jiang X, Butzkueven H, Duan Y, Huang J, Ren Z, Dong H, Shi FD, Barkhof F, Li K, Wang J. 2017. Multimodal characterization of gray matter alterations in neuromyelitis optica. Mult Scler. 2017;31(8):3278-3287.
  11. Fan M, Fu Y, Su L, Shen Y, Wood K, Yang L, Liu Y, Shi FD. 2017.Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. Mult Scler Relat Disord. 13:58-66.
  12. Su L, Han Y, Xue R, Wood K, Shi FD, Liu Y, Fu Y. 2016. Thalamic Atrophy Contributes to Low Slow Wave Sleep in Neuromyelitis Optica Spectrum Disorder. Aging Dis; 7:691-696.
  13. Shi K, Wang Z, Liu Y, Gong Y, Fu Y, Li S, Wood K, Hao J, Zhang GX, Shi FD, Yan Y. 2016. CFHR1-Modified Neural Stem Cells Ameliorated Brain Injury in a Mouse Model of Neuromyelitis Optica Spectrum Disorders. J Immunol. 197(9):3471-3480.
  14. Fu Y, Yan Y, Qi Y, Yang L, Li T, Zhang N, Yu C, Su L, Zhang R, Shen Y, Lin S, Liu Q, Shao Z, Han Z, Shi FD. 2016. Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2-Year Observational Study. CNS Neurosci Ther. 22(8):677-85.
  15. Qi Y, Jia K, Zhang DQ, Li T, Li LM, Zhang LJ, Wang J, Gao CL, Sun LS, Shi FD, Yang L. 2016. Increased resistin levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica. Clin Chim Acta. 456:176-9.
  16. Liu Q, Sanai N, Jin WN, La Cava A, Van Kaer L, and Shi FD. 2016. Neural stem cells sustain natural killer cells that dictate recovery from brain inflammation. Nat Neurosci. 19:243-52.
  17. Yan Y, Li YJ, Fu Y, Yang L, Su L, Shi K, Li M, Liu Q, Borazanci A, Liu Y, He Y, Bennett F, Vollmer T, Shi FD. 2016. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016 Feb 26.
  18. Shu N, Duan Y, Xia M, Schoonheim MM, Huang J, Ren Z, Sun Z, Ye J, Dong H, Shi FD, Barkhof F, Li K, Liu Y. 2016. Disrupted topological organization of structural and functional brain connectomes in clinically isolated syndrome and multiple sclerosis. Sci Rep. 6:29383.
  19. Zhang LJ, Zhao N, Fu Y, Zhang DQ, Wang J, Qin W, Zhang N, Wood K, Liu Y, Yu C, Shi FD, Yang L. 2015. Olfactory dysfunction in neuromyelitis optica spectrum disorders. J Neurol. 262(8):1890-8. 
  20. Pan J, Zhao P, Cai H, Su L, Wood K, Shi FD, Fu Y. 2015. Hypoxemia, Sleep Disturbances, and Depression Correlated with Fatigue in Neuromyelitis Optica Spectrum Disorder.CNS Neurosci Ther. 21(7):599-606.
  21. Liu Y, Duan Y, Huang J, Ren Z, Ye J, Dong H, Shi FD, Barkhof F, Vrenken H, Wattjes MP, Wang J, Li K. 2015. Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. Radiology. 4:142786.
  22. Liu Y, Fu Y, Schoonheim MM, Zhang N, Fan M, Su L, Shen Y, Yan Y, Yang L, Wang Q, Zhang N, Yu C, Barkhof F, Shi FD. 2015. Structural MRI substrates of cognitive impairment in neuromyelitis optica. Neurology. 27;85(17):1491-9.
  23. Liu Y, Liang P, Duan Y, Huang J, Ren Z, Jia X, Dong H, Ye J, Shi FD, Butzkueven H, Li K. 2015. Altered thalamic functional connectivity in multiple sclerosis. Eur J Radiol. 84(4):703-8. 
  24. Liu Y, Wang J, Daams M, Weiler F, Hahn HK, Duan Y, Huang J, Ren Z, Ye J, Dong H, Vrenken H, Wattjes MP, Shi FD, Li K, Barkhof F. 2015. Differential patterns of spinal cord and brain atrophy in NMO and MS. Neurology. 84(14):1465-72.
  25. Song Y, Pan L, Fu Y, Sun N, Li YJ, Cai H, Su L, Shen Y, Cui L, Shi FD. 2015. Sleep abnormality in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2(3):e94.
  26. Li YJ, Zhang F, Qi Y, Chang GQ, Fu Y, Su L, Shen Y, Sun N, Borazanci A, Yang C, Shi FD, Yan Y. 2015. Association of circulating follicular helper T cells with disease course of NMO spectrum disorders. J Neuroimmunol. 278:239-46
  27. Wang J, Li X, Zhang DQ, Yang CS, Qi Y, Li MS, Shi FD, Yang L.2015. Quantitative analysis of aquaporin-4 antibody in longitudinally extensive transverse myelitis.J Neuroimmunol. 278:26-9.
  28. Liu Y, Xie T, He Y, Duan Y, Huang J, Ren Z, Gong G, Wang J, Ye J, Dong H, Butzkueven H, Shi FD, Shu N, Li K. 2014.Cortical Thinning Correlates with Cognitive Change in Multiple Sclerosis but not in Neuromyelitis Optica.Eur Radiol. 24(9):2334-43.
  29. Su N, Shi SX, Zhu X, Borazanci A, Gan Y, Shi FD. 2014. Interleukin-7 expression and its effect on natural killer cells in patients with multiple sclerosis. J Neuroimmunol. 276(1-2):180-6.
  30. Yin JX, Tang Z, Gan Y, Li L, Shi FD, Coons S, Shi J. 2014.Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.Neuropharmacology. 81:1-5.
  31. Yang CS, Zhang DQ, Wang JH, Jin WN, Li MS, Liu J, Zhang CJ, Li T, Shi FD, Yang L. 2014.Clinical features and anti-aquaporin 4 antibody status in patients with demyelinating disorders of the central nervous system from Tianjin, China. CNS Neuroscience and Therapeutics. 20(1):32-9.
  32. Jordan C. Bell, Liu QW, Gan Y, Shi FD, Gregory Turner J. 2013. Visualization of neuropathology in murine model with rodent MRI. J. Neuroimmunol. 264(1-2):35-40.
  33. Yang CS, Yang L, Li T, Zhang DQ, Jin WN, Li MS, Su N, Zhang NN, Shao ZH, Yu CS, and Shi FD. 2013. Responsiveness to reduced dosage of rituximab in Chinese neuromyelitis optica patients. Neurology. 81:710-3. 影响因子:8.166.引用次数:46.
  34. Simard AR, Gan Y, St-Pierre S, Kousari A, Patel V, Whiteaker P, Morley BJ, Lukas RJ, Shi FD. 2013. Differential modulation of EAE by α9*- and β2*-nicotinic acetylcholine receptors. Immunol Cell Biol. 91(3):195-200.
  35. Kim do Y, Hao J, Liu R, Turner G, Shi FD, Rho JM. 2012. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. Plos One. 7:e35476.
  36. Gan Y, Liu R, Wu W, Bomprezzi R, Shi FD. 2012. Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol.15;247(1-2):9-15.
  37. Liu JQ, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, Yu C, Shi FD, Whitacre CC, Trgovcich J, Bai XF. 2012. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol. 188:3099-106.
  38. Hao JW, Campagnolo DI, Liu R, Piao WH, Shi S, Hu B, Xiang R, Zhou Q, Vollmer TL, Van Kaer L, La Cava A, and Shi FD. 2011. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol. 69:721-34. 影响因子:9.638. 引用次数:52.
  39. Hao JW, Simard AR, Turner GH, Wu J, Whiteaker P, Lukas RJ, and Shi FD. 2010. Attenuation of CNS inflammatory responses by nicotine involves a7 and non-a7 nicotinic receptors. Exp Neurol. 227:110-119.
  40. Hao JW, Liu R, Piao WH, Zhou Q, Vollmer TL, Xiang R, La Cava A, Campagnolo DI, Van Kaer L, and Shi FD. 2010. CNS-resident NK cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med. 207:1907-1921. 影响因子:11.24. 引用次数:146. 封面文章和Nature专题报道“Killer cells help”.
  41. Yin JX, Tu JL, Lin HJ, Shi FD, Liu RL, Zhao CB, Coos SW, Kuniyoshi S, and Shi J. 2010. Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model.PLoS One. 5:e12400.
  42. Kala M, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, and Vollmer TL. 2010. B Cells from Glatiramer Acetate-Treated Mice Suppress Experimental Autoimmune Encephalomyelitis. Exp Neurol. 221:136-145.
  43. Bar-Or A, Oger J, Gibbs E, Niino M, Aziz T, Renoux C, Alatab S, Shi FD, Campagnolo DI, Jalili F, Rhodes S, Yamashita T, Fan B, Freedman MS, Panitch H, Arnold DL, and Vollmer T. 2009. Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression? Mult Scler. 15:959-964.
  44. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Lukas R, and Vollmer TV. 2009. Nicotinic attenuation of central nervous system inflammation and autoimmunity. J Immunol.182:1730-1739.
  45. Zhao CB, Coons SW, Cui M, Shi FD, Vollmer TL, Ma CY, Kuniyoshi SM, Shi J. 2008. A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin. Biochem Biophys Res Commun. 370:16-21.
  46. Liu R, Bai Y, Vollmer TL, Bai XF, Jee YH, Tang Y, Campagnolo DI, Collins M, Young DA, La Cava A, and Shi FD. 2008. IL-21 Receptor Expression Determines the Temporal Phases of Experimental Autoimmune Encephalomyelitis. Exp Neurol. 211:14-24.
  47. Piao WH, Jee YH, Liu R, Coons SW, Kala M, Collins M, Young DA, Campagnolo DI, Vollmer TL, Bai XF, La Cava A, and Shi FD. 2008. IL-21 Modulates CD4+CD25+ Regulatory T cell homeostasis in EAE. Scand J Immunol. 67:37-46.
  48. Bar-Or A, Vollmer TL, Antel J, Bodner CA, Campagnolo DI, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, and Garren H. 2007. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase I/II trial. Arch Neurol. 64:1407-1415.
  49. Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Campagnolo DI, Shi FD, and Vollmer TL. 2007. CD4+CD25+ regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis.Clin Immunol. 125:34-42.
  50. Liu JQ, Carl JW Jr, Joshi PS, Raychaudhury A, Pu XA, Shi FD, and Bai XF. 2007. CD24 on the resident cells of the central nervous system enhances experimental autoimmune encephalomyelitis. J Immunol.178:6227-6235.
  51. Huang D*, Shi FD*, Jung S, Pien GC, Wang J, Salazar-Mather TT, He T, Weaver J, Ljunggren HJ, Biron CA, Littman DR., and Ransohoff RM. 2006. CX3CR1 mediates specific recruitment to the central nervous system of NK cells that modify disease expression in experimental autoimmune encephalomyelitis. FASEB J.20:896-905. (*co-first author).
  52. Jee Y, Liu R., Bai XF, Campagnolo D, Shi FD, Vollmer TL. 2006. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? Int Immunol. 18:537-544.
  53. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. 2005. Differential effects of IL-21 in the initiation and progression of autoimmunity against neuroantigens. J Immunol. 174:2696-2701.
  54. Shi FD, Takeda K, Akiro S, Sarvetnick N, and Ljunggren HG. 2000. Interleukin-18 directs autoreactive T cells and promotes autodestruction in the central nervous system by induction of IFN-g by natural killer cells. J Immunol. 165:3099-3104.
  55. Liu JQ, Bai XF, Shi FD, Xiao BG, Li HL, Levi M, Mustafa M, Wahren B, and Link H. 1998. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.Int Immunol.10:1139-48.
  56. Bai X, Li H, Shi FD, van der Meide PH, and Link H. 1998. Complexities of a applying nasal tolerance induction as therapy for ongoing experimental autoimmune encephalomyelitis in DA rats. Clin Exp Immunol. 111:205-210.
  57. Bai X, Shi FD, Li H, van der Meide PH, and Link H. 1997. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-b mRNA. J Neuroimmunol.80:65-75.

重症肌无力:

代表性论文发表在Nat Immunol. 1

  1. Li Z, Li M, Wood K, Hettwer S, Muley SA, Shi FD, Liu Q, Ladha SS. 2017. Engineered Agrin Attenuates the Severity of Experimental Autoimmune Myasthenia Gravis. Muscle Nerve. doi: 10.1002/mus.26025.
  2. Zhang CJ, Gong Y, Zhu W, Qi Y, Yang CS, Fu Y, Chang G, Li Y, Shi S, Wood K, Ladha S, Shi FD, Liu Q, Yan Y. 2016. Augmentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis. J Immunol. 197(7):2610-7.
  3. Zhang N, Li YJ, Fu Y, Shao JH, Luo LL, Yang L, Shi FD, Liu Y. 2015. Cognitive impairment in Chinese neuromyelitis optica. Mult Scler. 21(14):1839-46.
  4. Sun F, Ladha S, Yang L, Li T, Liu Q, Shi S, Su N, Bomprezzi R, and Shi FD. 2014. IL-10 producing B cells in myasthenia gravis during rituximab therapy. Muscle and Nerve. 49(4):487-94.
  5. Wu W, Shi S, Ljunggren HG, La Cava A, Van Kaer L, Shi FD, and Liu R. 2012. NK cells inhibit T-bet deficient autoreactive Th-17 cells. Scand J Immunol. 76(6):559-66.
  6. Shi QG, Wang ZH, Ma XW, Zhang DQ, Yang CS, Shi FD, Yang L. 2012. Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis. Neurosci Bull. 28 (5): 469-74.
  7. Liu R, Zhou QH, La Cava A, Van Kaer L, Campagnolo DI, and Shi FD. 2010.Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complex suppresses experimental myasthenia. Eur J Immunol. 40:1577-1589.
  8. Liu R, Hao JW, Dayao C, Vollmer TL, Shi FD, and Campagnolo DI. 2009. T-bet deficiency decreases susceptibility to experimental myasthenia gravis. Exp Neurol. 220: 366-373.
  9. Bai Y, Liu R, Huang D, La Cava A., Tang YY, Iwakura Y, Campagnolo DI, Vollmer TL, Ransohoff RM, and Shi FD. 2008. CCL2 Recruitment of IL-6-producing CD11b+ Monocytes to the Draining Lymph Nodes during the Initiation of Th17-dependent B cell-mediated Autoimmunity. Eur J Immunol. 38:1877-1888.
  10. Bakhiet M, Yu LY, Ozenci V and Shi FD. 2006. Modulation of immune responses and suppression of experimental autoimmune myasthenia gravis by surgical denervation of the spleen. Clin Exp Immunol. 144:290-298.
  11. Liu R, Van Kaer L, La Cava A, Price M, Rhodes S, Campagnolo D, Vollmer T, and Shi FD. 2006. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol.176:5247-5254.
  12. Liu R., La Cava A, Campagnolo D, Price M, Vollmer L, Van Kaer L, and Shi FD. 2005. Cooperation of iNKT cells and CD4+CD25+ Treg cells in the prevention of autoimmune myasthenia. J. Immunol. 175:7898-7904.
  13. Shi FD, Flodstrom M, Kim SH, Pakala S, Cleary M, Ljunggren HG, and Sarvetnick N. 2001. Control of autoimmune response by type 2 nitric oxide synthase. J Immunol. 167:3000-3006.
  14. Wang H*, Shi FD*, Li H, Chambers BJ, Link H, and Ljunggren HG. 2001. CTLA4 blockade induces intramolecular determinant spreading and enhances murine myasthenia gravis. J Immunol. 166:6430-6436. (*co-first author).
  15. Huang D, Shi FD, Giscombe R., Ljunggren HG, and Lefvert A. 2001. Interleukine-1b gene disruption diminishes acetylcholine receptor induced immune responses in experimental autoimmune myasthenia gravis in mice. Eur J Immunol.  31:225-232.
  16. Shi FD, Wang H, Li H, Hong S, Tanihuchi M, Link H, Van Kaer L, and Ljunggren HG. 2000. Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol. 1:245-251.
  17. Wang HB, Shi FD, Li H, van der Meide PH, Ljunggren HG, and Link H. 2000. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Clin Immunol. 95:156-62.
  18. Wang H, Li H, Shi FD, Chambers B, Link H, and Ljunggren HG. 2000. Tumor necrosis factor receptor 1 (TNFR1) is critically involved in murine experimental autoimmune myasthenia gravis. Int. Immunol. 12:1381-1388.
  19. Shi FD, Li H, Wang H, Bai X, van Der Meide PH, Link H, and  Ljunggren HG. 1999. Mechanisms of nasal tolerance in experimental autoimmune myasthenia gravis: Identification of the regulatory cells. J Immunol. 162:5757-5763.
  20. Li HL, Shi FD, Bai XF, Huang YM, van der Meide PH, Xiao BG, and Link H. 1998. Nasal tolerance to experimental autoimmune myasthenia gravis: tolerance reversal by nasal administration of minute amounts of interferon-gamma.Clin Immunol Immunopathol. 87:15-22.
  21. Zhang GX, Shi FD, Zhu J, Xiao BG, Levi M, Wahren B, Yu LY, and Link H. 1998. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis.J Neuroimmunol. 85:96-101.
  22. Xiao BG, Zhang GX, Shi FD, Ma CG, and Link H. 1998. Decrease of LFA-1 is associated with upregulation of TGF-beta in CD4(+) T cell clones derived from rats nasally tolerized against experimental autoimmune myasthenia gravis.Clin Immunol Immunopathol. 89:196-204.
  23. Li H, Shi FD, Bai X, Huang Y, Diab A, He B, and Link H. 1998. Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis.J Neurol Sci.161:40-6.
  24. Li H, Shi FD, He B, Backheit M, Wahren B, Berglöf A, Sandstedt K, and Link H. 1998. Experimental autoimmune myasthenia gravis induction in B cell deficient mice. Int Immunol. 10:1359-1365.
  25. Shi FD, van der Meide PH, and Link H. 1998. Nasal tolerance in experimental autoimmune myasthenia gravis: induction of protective tolerance in primed animals. Clin Exp Immunol. 111:506-512.
  26. Shi FD, Bai X, Li H, and Link H. 1998. Macrophages apoptosis in muscle tissues in experimental autoimmune myasthenia gravis. Muscle & Nerve 21:1071-1074.
  27. Shi FD, He B, Li H, Matusevicius D, Link H, and Ljunggren HG. 1998. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur J Immunol. 28:3587-3593.
  28. Zhang GX, Yu LY, Shi FD, Xiao BG, Björk J, Hedlund G, and Link H. 1997. Linomide suppresses both Th1 and Th2 cytokines in experimental autoimmune myasthenia gravis.J Neuroimmunol. 73:175-82.
  29. Shi FD, Bai X, Xiao B, van der Meide PH, and Link H. 1998. Nasal tolerance of multiple antigens suppresses experimental autoimmune myasthenia gravis (EAMG), encephalomyelitis (EAE), and neuritis (EAN). J Neurol Sci. 155:1-12.
  30. Shi FD, Zhang G, Bai X, van der Meide PH, and Link H. 1997. Cellular mRNA expression of IFN-g, IL-4 and IL-10 relates to the resistance to experimental autoimmune myasthenia gravis in young Lewis rats. Clin Exp Immunol. 108:523-527.

缺血性卒中:

代表性论文发表在Immunity 1, PNAS 3, Circulation 1

        1. Feng Y, Liao S, Wei C, Jia D, Wood K, Liu Q, Wang X, Shi FD, Jin WN.Infiltration and persistence of lymphocytes during late­stage cerebral ischemia in middle cerebral artery occlusion and photothrombotic stroke models. J Neuroinflammation. 2017 Dec 15;14(1):248. doi: 10.1186/s12974­017­1017­0.
        2. Zhang F, Yan C, Wei C, Yao Y, Ma X, Gong Z, Liu S, Zang D, Chen J, Shi FD, Hao J. 2017. Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients. Transl Stroke Res. doi: 10.1007/s12975-017-0549-z.
        3. Zhang S, Zhou Y, Zhang R, Zhang M, Campbell B, Lin L, Shi FD, Lou M. 2017. Rationale and design of combination of an immune modulator Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) trial. Int J Stroke.:1747493017710340. doi: 10.1177/17474930 17710340.
        4. Liu Q, Jin WN, Liu Y, Shi K, Sun H, Zhang F, Zhang C, Gonzales R, Sheth KN, La Cava A, Shi FD. 2017. Brain ischemia suppresses immunity in the periphery and brain via different neurogenic innervations. Immunity. 46:474-487. 影响因子:24.082. 引用次数:6.

Immunity社论专题评述: Linda Quatrini1 and Sophie Ugolini1, Disarming the Killers: Brain Strikes on NK Cells. DOI: http://dx.doi.org/10.1016/j.immuni.2017.03.001.

        1. Li M, Li Z, Yao Y, Jin WN, Wood K, Liu Q, Shi FD, Hao J. 2017. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc Natl Acad Sci U S A. 2017;114: E396-E405.影响因子:9.423. 引用次数:5.
        2. Yao Y, Miao W, Liu Z, Han W, Shi K, Shen Y, Li H, Liu Q, Fu Y, Huang D, Shi FD. 2016. Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice. Transl Stroke Res. 7(6):535-547.
        3. Li D, Wang C, Yao Y, Chen L, Liu G, Zhang R, Liu Q, Shi FD, Hao J. 2016. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. FASEB J. 30(10):3388-3399.
        4. Jin WN, Yang X, Li Z, Li M, Shi X, Wood K, Fu Y, Han W, Xu Y, Shi FD, Liu Q. 2016. Non-invasive tracking of     CD4+ T cells with a paramagnetic and fluorescent nanoparticle in brain ischemia. J Cereb Blood Flow Metab.36(8):1464-76.
        5. Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, Dong Y, Xu X, Liu Q, Huang D, Shi FD. 2015. Combination of an immune modulator fingolimod with alteplase in acute ischemic stroke. Circulation. 132:1104-12. 影响因子:17.047. 引用次数:48.
        6. Yue X, Tian L, Fan X, Xu G, Shi FD, Liu X. 2015. Chromosome 9p21.3 Variants Are Associated with Cerebral Infarction in Chinese Population. J Mol Neurosci. 56(3):546-52.
        7. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, Han W, Xue R, Liu Q, Hao J, Yu C, Shi FD. 2014. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 111:18315-20.影响因子:9.423. 引用次数:61.
        8. Tang ZW, Gan Y, Yin JX, Liu Q, Shi J, Shi FD. 2014.CX3CR1 deficiency suppresses proliferation and neurotoxicity of macrophage/microglia in MCAO mice. J. Neuoinflammation.11:26.
        9. Zhang J, Meng LL, Qin W, Liu NN, Xue R, Shi FD, Yu CS.2014.Structural damage and functional compensation in ipsilesional M1 after stroke. Stroke, 45(3):788-93.
        10. Gan Y, Liu Q, Wu W, Yin J, Tang Z, Turner G, Chen J, Wang Y, Lanrent J, Yokayama W, Shi FD. 2014. Ischemic neurons recruit NK cells that accelerate brain infarction. Proc Natl Acad Sci USA. 111:2704-9. 影响因子:9.423. 引用次数:63.
        11. Liu Q, Tang ZW, Gan Y, Wu W, Kousari A, Shi FD. 2014.Genetic deficiency of β2-nAChRs attenuates brain Injury in ischemic stroke. Neuroscience. 256:170-7.

出血性卒中:

代表性论文发表在JAMA Neurology 1

  1. Zhang J, Shi K, Li Z, Li M, Han Y, Wang L, Zhang Z, Yu C, Zhang F, Song L, Dong JF, La Cava A, Sheth KN, Shi FD. 2018. Organ- and cell-specific immune responses are associated with the outcomes of intracerebral hemorrhage. FASEB J.32(1):220-229
  2. Sreekrishnan A, Leasure AC, Shi FD, Hwang DY, Schindler JL, Petersen NH, Gilmore EJ, Kamel H, Sansing LH, Greer DM, Sheth KN. 2017. Functional Improvement Among Intracerebral Hemorrhage (ICH) Survivors up to 12 Months Post-injury. Neurocrit Care. doi: 10.1007/s12028-017-0425-4.
  3. Li M, Ren H, Sheth KN, Shi FD, Liu Q. 2017. A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J. pii: fj.201601377RR. doi: 10.1096/fj.201601377RR.
  4. Sreekrishnan A, Dearborn JL, Greer DM, Shi FD, Hwang DY, Leasure AC, Zhou SE, Gilmore EJ, Matouk CC, Petersen NH, Sansing LH, Sheth KN. 2016. Intracerebral Hemorrhage Location and Functional Outcomes of Patients: A Systematic Literature Review and Meta-Analysis. Neurocrit Care.25(3):384-391.
  5. Grunwald Z, Beslow LA, Urday S, Vashkevich A, Ayres A, Greenberg SM, Goldstein JN, Leasure A, Shi FD, Kahle KT, Battey TW, Simard JM, Rosand J, Kimberly WT, Sheth KN. 2016. Perihematomal Edema Expansion Rates and Patient Outcomes in Deep and Lobar Intracerebral Hemorrhage. Neurocrit Care. 2016 Nov 14.
  6. Li M, Li Z, Ren H, Jin WN, Wood K, Liu Q, Sheth KN, Shi FD. 2016. Colony stimulating factor 1 receptor inhibition eliminates microglia and attenuates brain injury after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2016 Sep 5. pii: 0271678X16666551.
  7. Sun N, Shen Y, Han W, Shi K, Wood K, Hao J, Liu Q, Sheth K, Huang D, Shi FD. 2016. Selective sphingosine-1-phosphate receptor 1 modulation attenuates experimental intracerebral hemorrhage. Stroke. 47(7):1899-906.
  8. Li YJ, Chang GQ, Liu Y, Gong Y, Yang C, Wood K, Shi FD, Fu Y, Yan Y. 2015. Fingolimod alters inflammatory mediators and vascular permeability in intracerebral hemorrhage. Neurosci Bull. 2015;31(6):755-62.
  9. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, Yan Y, Huang D, Yu C, Shi FD. 2014. Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study. JAMA Neurol. 71:1092-101. 影响因子:8.23. 引用次数:82.

美国心脏病学学会(AHA)头版头条报道:“Stroke Rounds: An MS Drug for ICH?”; JAMA Neurology社论专题评述:Kevin N. Sheth and Jonathan Rosand, Targeting the Immune System in Intracerebral Hemorrhage. 2014;71:1083-4.

格林-巴利综合征:

  1. Zhang CJ, Zhai H, Yan YP, Hao JW, Li MS, Jin WN, Vollmer TL, Shi FD. 2014.Glatiramer acetate ameliorates experimental autoimmune neuritis. J. Immunol. Cell Bio. 92(2):164-9.
  2. Bai XF, Shi FD, Zhu J, Xiao BG, Hedlund G, and Link H. 1997. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions.J Neuroimmunol.76:177-84.

神经系统感染性疾病:

  1. Zhang C, Xie B, Shi FD, Hao J. 2014. Multiple intracranial arteritis and hypothyroidism secondary to Streptococcus anginosus infection. J Neurol Neurosurg Psychiatry. 86(9):1044-5. 
  2. Diab D, Abdalla H, Li H, Shi FD, Bakhiet M, and Link H. 1999. Neutralization of MIP-2 and MIP-1a  attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infec Immunity67:2590-2601.

其它自身免疫疾病:

代表性论文发表在PNAS 1

  1. Liu Y, Liu A, Iikuni N, Xu H, Shi FD, La Cava A. 2014.Regulatory CD4+ T cells promote B cell anergy in murine lupus. J Immunol. 192(9):4069-73.
  2. Amarilyo G, Lourenço EV, Shi FD, La Cava A. 2014.IL-17 promotes murine lupus. J Immunol. 193(2):540-3.
  3. Yu Y, Liu Y, Shi FD, Zou H, Matarese G, La Cava A. 2013. Cutting Edge: Leptin-Induced RORγt Expression in CD4+ T Cells Promotes Th17 Responses in Systemic Lupus Erythematosus. J Immunol. 190(7):3054-8.
  4. Yu Y, Liu Y, Shi FD, Zou H, Hahn BH, La Cava A. 2012. Tolerance induced by anti-DNA Ig peptide in (NZB×NZW) F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells. Clin Immunol. 142:291-5.
  5. Tybl E, Shi FD, Kessler SM, Tierling S, Walter J, Bohle RM, Wieland S, Zhang J, Tan E.M, and Kiemer AK. 2011. Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype. J hepatol.54:994-1001.
  6. Lourenço EV, Procaccini C, Ferrera F, Iikuni N, Singh RP, Filaci G, Matarese G, Shi FD, Brahn E, Hahn BH, and La Cava A. 2009. Modulation of p38 MAPK activity in regulatory T cells after anti-DNA Ig peptide in (NZB x NZW) F1 lupus mice. J Immunol.182:7415-7421.
  7. Ferrera F, Hahn BH, Rizzi M, Anderson M, FitzGerald J, Millo E, Indiveri F, Shi FD, and La Cava A. 2007. Somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide protects (NZB x NZW)F1 Lupus-prone mice from renal disease. Arth Rheum. 56:1945-1953.
  8. Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL, Wilson SB, and Sarvetnick N. 2001. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA. 58:6777-6782. 影响因子:9.423. 引用次数:195.

癫痫:

  1. Feng ZH, Hao J, Ye L, Dayao C, Yan N, Yan Y, Chu L and Shi FD. 2011. Overexpression of m-calpain in the anterior temporal neocirtex of patients with intractable epilepsy correlates with clinicopathological characteristics. Seizure. 20:395-401.

阿尔茨海默氏病/帕金森氏症:

  1. Wu W, Cui L, Fu Y, Tian Q, Liu L, Zhang X, Du N, Chen Y, Qiu Z, Song Y, Shi FD, Xue R. 2016. Sleep and Cognitive Abnormalities in Acute Minor Thalamic Infarction. Neurosci Bull. 32(4):341-8.
  2. Zhang N, Wei C, Du H, Shi FD, Cheng Y. 2015. The Effect of Memantine on Cognitive Function and Behavioral and Psychological Symptoms in Mild-to-Moderate Alzheimer's Disease Patients. Dement Geriatr Cogn Disord. 40(1-2):85-93. 
  3. Zhang N, Xing M, Wang Y, Liang H, Yang Z, Shi FD, Cheng Y. 2014.Hydroxysafflor yellow A improves learning and memory in a rat model of vascular dementia by increasing VEGF and NR1 in the hippocampus.Neurosci Bull. 30(3):417-24.
  4. Qin W, Jia L, Zhou A, Zuo X, Cheng Z, Wang F, Shi FD, Jia J. 2011. The -980C/G polymorphism in APH-1A promoter confers risk of Alzheimer’s disease. Aging Cell. 10:711-9.

创伤性脑损伤:

  1. Zhou Y, Cai W, Zhao Z, Hilton T, Wang M, Yeon J, Liu W, Zhang F, Shi FD, Wu X, Thiagarajan P, Li M, Zhang J, Dong JF. Lactadherin Promotes Microvesicle Clearance to Prevent Coagulopathy and Improves Survival of Severe TBI Mice. Blood. 2017 Nov 21. pii: blood-2017-08-801738.
  2. Kong XD, Bai S, Chen X, Wei HJ, Jin WN, Li MS, Yan Y, Shi FD. 2014. Alterations of natural killer cells in traumatic brain injury. Neurosci Bull. 30(6):903-12.

脑及其它部位肿瘤:

  1. Jin S, Deng Y, Hao JW, Li Y, Liu B, Yu Y, Shi FD, Zhou QH. 2014. NK cell phenotypic modulation in lung cancer environment. PLoS One.9(10):e109976.
  2. Hao J, Shi FD, Abdelwahab M, Shi SX, Simard A, Whiteaker P, Lukas R, Zhou Q. 2013. Nicotinic Receptor β2 Determines NK Cell-Dependent Metastasis in a Murine Model of Metastatic Lung Cancer. PLoS One. 8(2):e57495.
  3. Kushchayev SV, Sankar T, Eggink LL, Kushchayeva YS, Wiener PC, Hoober JK, Eschbacher J, Liu R, ShiFD, Abdelwahab MG, Scheck AC, Preul MC. 2012. Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part 1: stimulatory effects on blood monocytes and monocyte-derived cells of the brain. Cancer Manag Res. 4:309-23.
  4. Kushchayev SV, Sankar T, Eggink LL, Kushchayeva YS, Wiener PC, Hoober JK, Eschbacher J, Liu R, Shi FD, Abdelwahab MG, Scheck AC, Preul MC. 2012. Monocyte galactose/N-acetylgalactosamine-specific C-type lectin receptor stimulant immunotherapy of an experimental glioma. Part II: combination with external radiation improves survival. Cancer Manag Res. 4:325-34.
  5. Piao WH, Wong R, Bai XF, Campagnolo DI, Dorr RT, Vollmer TL, and Shi FD. 2007. Therapeutic effect of anthracene-based anti-cancer agent ethonafide in an animal model of multiple sclerosis. J Immunol.179:7415-7423.
  6. Joshi PS, Liu J, Wang Y, Chang X, Richards J, Shi FD, Ljunggren HG, and Bai XF. 2006. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leuk Biol. 80:1345-1353.
  7. Looi K, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. 2006. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 16:1105-10.
  8. Megliorino R., Shi FD, Tan EM, Zhang JY. 2005. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev. 29:241-248.
  9. Shi FD, Zhang J, Casiano CA, Chan EK, and Tan EM. 2005. Preferential humoral immune response to p90 in prostate cancer. Prostate 63:352-358.
  10. Koziol JA, Zhang J, Casiano CA Shi FD, Feng A, Chan EK, and Tan EM. 2003. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res. 9:5120-5126.

其它:

  1. Liu Q, Xin W, He P, Turner D, Yin J, Gan Y, Shi FD, Wu J. 2014. Interleukin-17 inhibits Adult Hippocampal Neurogenesis. Sci Rep. 2014 Dec 19; 4:7554. doi: 10.1038/srep07554.
  2. Schwartz E I, Smilenov L B, Price M A, Osredkar T, Baker R A, Ghosh S, Shi FD, Vollmer T, Lencinas L A, Stearns D M, Gorospe M, and Kruman II. 2007. Cell cycle activation in postmitotic neurons is essential for DNA repair. Cell Cycle6:318-329.

 

评论性论文:

代表性论文发表在Nat Rev Neurol 1, Neurology 2, Nat Rev Immunol 2

  1. Shi FD. 2015. Neuroinflammation.Neurosci Bull. 31(6):714-6.
  2. Fu Y, Liu Q, Anrather J, Shi FD. 2015. Immune interventions in stroke. Nat Rev Neurol. 11(9):524-35. 
  3. Shi FD, Yang CS, Yang L, Li T, Jin WN. 2014. Author response. Neurology. 82(6):547.
  4. Xiao J, Simard AR, Shi FD, Hao J. 2014 New Strategies in the Management of Guillain-Barré Syndrome.Clin Rev Allergy Immunol. 47(3):274-88. 
  5. Yao Y, Simard AR, Shi FD, Hao J. 2013. IL-10-Producing Lymphocytes in Inflammatory Disease. Int Rev Immunol. 32(3):324-36.
  6. Shi FD, Jia JP. 2011. Neurology and neurologic practice in China. Neurology. 77:1986-92.
  7. Shi FD, Ljunggren HG, La Cava A, Van Kaer L. 2011. Organ-specific features of natural killer cells. Nat Rev Immunol. 11:658-71.
  8. Shi FD, Zhou QH. 2011. NK cells as an indispensable disease players and therapeutic target in autoimmune disorders. Autoimmunity. 44:3-10.
  9. Flodström-Tullberg M, Bryceson YT, Shi FD, Höglund P, and Ljunggren HG. 2009. NK cells in human autoimmunity. Curr Opin Immnol. 21:634-640.
  10. Cai C, Shi FD, Matarese G, and La Cava A. 2009. Leptin as clinical target. Recent Pat Inflamm Allergy Drug Discov. 3:160-166.
  11. Piao WH, Campagnolo DI, Dayao C, Lukas RJ, and Shi FD. 2009. Nicotine and inflammatory neurological disorders. Acta Pharmacol Sin. 30:715-722.
  12. Shi FD andVan Kaer L. 2006. Reciprocal regulation between NK cells and autoreactive T cells. Nat Rev Immunol. 6:751-760.
  13. La Cava A, Van Kaer L, and Shi FD. 2006. CD4+CD25+ regulatory T cells and NKT cells: regulators regulating regulators. Trends Immunol. 27: 322-327
  14. La Cava A and Shi FD. 2006. Natural and adaptive immune cell-based therapies in autoimmunity. Curr Med Chem.13: 1557-1566.
  15. Tan EM and Shi FD. 2003. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin Exp Immunol. 134:169-177.
  16. Flodstrom M, ShiFD, Sarvetnick N, Ljunggren HG 2002. Natural killer cells, friend or foe in autoimmune disease. Scand J Immunol. 55:432-441.
  17. Shi FD, Ljunggren .G, and Sarvetnick N. 2001. Innate immunity and autoimmunity: from-self protection to self-aggression. Trends Immunol. 22:97-101.
  18. Shi FD, Ljunggren HG, and Sarvetnick N. 2001. Autoimmunity mediated by innate immune effector cells. Trends Immunol. 22:301.
  19. Wang HB, Li H, He B, Bakheit M, Levi M, Wahren B, Berglöf A, Sandstedt K, Link H, and Shi FD. 1999. “The role of B-cells in experimental myasthenia gravis in mice”.Biomed Pharmacother. 53:227-33.
  20. Zhang GX, Yu LY, Shi FD, Xiao BG, Björk J, Hedlund G, and Link H. 1998. Cytokine profiles of experimental autoimmune myasthenia gravis after treatment by the synthetic immunomodulator linomide”.Ann N Y Acad Sci. 841:580-3.